Design (Testphase)
Risk & Weakness
Going Concern (Distress Proxy)
159
Findings
July 21, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 25 hits from US
Going concern refers to serious doubt about whether a company can continue to operate. This scanner takes the classic warning signs: Altman Z″ in the distress zone (<1.1), interest coverage <1 (earnings don't cover interest), and negative operating cash flow (burning cash). Note: this is a quantitative proxy, NOT the actual auditor's note from the annual report — we could add that via an EDGAR text search ('substantial doubt … going concern').
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(17)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Altman Z-Score
- A bankruptcy early-warning system developed by Edward Altman: several balance-sheet ratios are combined into one score. Values above 3 are considered a safe zone, values below about 1.1 a distress zone with elevated bankruptcy risk.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Going Concern
- The assumption in a company's annual report that it can continue operating. If auditors raise "substantial doubt" about this, it is one of the sharpest warnings there is - the company could run out of cash.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIAV Viavi Solutions Inc | 08/06 | +127 % | 72 7/25 | Stage 2 | C -4 | 4 of 9 | 12.6 | Communication Equipment | Sells AI | — | — | Technology | 39.40 $ | +180.4 % | +159.6 % | +413.6 % | −16.5 % | +28.0 % | 98 | 9 | 8.6 % | 8.4 % | 1.19 | — | 33.3 | 9.3 | 14.7 | 278.0 | 1.34 | 91.7 | 12.2 % | 60.7 % | -4.0 % | -7.0 % | 3.6 % | 7.85 | 33.5 % | +8.4 % | 0.0 % | 0.0 % | -85.0 | 97.3 % | 8.3 % | 1.6 (9) |
| AIP Arteris Inc | 08/04 | +177 % | 61 6/25 | Stage 2 | C -5 | 3 of 9 | 2.1 | Semiconductors | Sells AI | — | — | Technology | 30.70 $ | +165.9 % | +197.1 % | +372.2 % | −3.8 % | -13.4 % | 98 | 42 | 7.1 % | 7.5 % | 1.92 | — | 0.0 | 26.8 | 731.2 | — | — | -7.7 | -38.0 % | 88.8 % | -44.9 % | -1,369.6 % | -17.9 % | 2.11 | 1.8 % | +22.3 % | 0.0 % | 0.0 % | -3.7 | 61.1 % | 6.5 % | 1.3 (4) |
| INBX Inhibrx Biosciences, Inc. | 08/12 | — | 55 5/22 | Stage 2 | D -37 | 2 of 9 | 1.5 | Biotechnology | Neutral | — | — | Healthcare | 84.10 $ | +17.6 % | +18.8 % | +553.4 % | −38.6 % | +191.2 % | 97 | 42 | 6.9 % | 7.5 % | 3.43 | — | 0.0 | 1,120.8 | 212.3 | — | — | 0.0 | — | -7,697.5 % | 0.0 % | -354.7 % | -36.1 % | -0.28 | — | +550.0 % | 0.0 % | 0.0 % | -1.0 | 83.1 % | 30.1 % | — |
| HYMC Hycroft Mining Holding Corporation | 07/29 | +212 % | 51 5/23 | Stage 1 | D -22 | 4 of 9 | 2.0 | Gold | Neutral | — | — | Basic Materials | 18.80 $ | -2.7 % | -6.3 % | +573.9 % | −62.7 % | -40.6 % | 97 | 42 | 8.2 % | 8.0 % | 2.72 | — | 0.0 | — | 9.7 | — | — | -0.8 | — | -341.0 % | 0.0 % | -86.1 % | -26.8 % | 0.00 | — | -100.0 % | 0.0 % | 0.0 % | 0.6 | 33.1 % | 19.4 % | — |
| OTLK OUTLOOK THERAPEUTICS INC | 08/13 | -32 % | 71 6/22 | Stage 3 | D -42 | 4 of 9 | 0.2 | Biotechnology | Uses AI | — | Healthcare | 1.40 $ | +7.6 % | -7.7 % | +0.0 % | −52.5 % | +241.6 % | 97 | 42 | 16.8 % | 20.7 % | 0.78 | — | 2.8 | 790.0 | — | — | — | -4.1 | — | -360.8 % | 0.0 % | -3.7 % | -184.8 % | — | — | +730.9 % | 0.0 % | 0.0 % | -116.1 | 6.9 % | 10.1 % | — | |
| ABSI Absci Corp | 08/11 | +106 % | 5 1/22 | Stage 2 | D -48 | 3 of 9 | 1.8 | Biotechnology | Sells AI | — | — | Healthcare | 8.20 $ | +112.3 % | +218.8 % | +265.0 % | −9.2 % | +27.3 % | 96 | 42 | 16.7 % | 12.8 % | 2.33 | — | 0.0 | 928.4 | 9.1 | — | — | -0.4 | — | -4,455.0 % | 0.0 % | -63.9 % | -37.3 % | 0.03 | — | -38.2 % | 0.0 % | 0.0 % | -0.3 | 72.9 % | 26.6 % | — |
| FIRY FIRY | 08/06 | -24 % | — | Stage 2 | C -9 | 4 of 9 | 0.0 | Electronic Gaming & Multimedia | Sells AI | — | Communication Services | 8.60 $ | +111.6 % | -36.1 % | +25.9 % | −58.2 % | — | 95 | 42 | 11.2 % | 11.7 % | 4.54 | — | 0.0 | — | 1.3 | — | — | -0.2 | — | 87.8 % | -57.5 % | -49.6 % | -12.5 % | 1.26 | — | -31.3 % | 0.0 % | 0.0 % | -9.1 | 37.8 % | 23.4 % | — | |
| IBRX Immunitybio Inc | 08/04 | +57 % | 56 5/22 | Stage 2 | C +1 | 3 of 9 | 8.0 | Biotechnology | Uses AI | — | — | Healthcare | 7.50 $ | +269.7 % | +309.8 % | +182.6 % | −37.3 % | +66.9 % | 94 | 42 | 7.8 % | 7.0 % | 0.08 | — | 0.0 | 57.1 | — | — | — | -9.0 | -157.9 % | 99.3 % | 0.0 % | 0.0 % | -34.4 % | — | -134.5 % | +668.3 % | 0.0 % | 0.0 % | -23.1 | 17.6 % | 34.8 % | 1.0 (5) |
| QMCO Quantum Corporation | — | -32 % | 62 6/25 | Stage 2 | D -17 | 4 of 9 | 0.4 | Computer Hardware | Uses AI | — | — | Technology | 11.00 $ | +114.1 % | +60.8 % | +63.9 % | −30.0 % | +27.6 % | 94 | 42 | 14.0 % | 14.5 % | 2.96 | — | 1.9 | 1.4 | 0.1 | — | 0.77 | 236.9 | — | 36.9 % | -36.1 % | 0.0 % | -6.6 % | -0.04 | — | -12.1 % | 0.0 % | 0.0 % | -26.0 | 12.8 % | 7.0 % | — |
| RFL Rafael Holdings, Inc. | — | +9 % | 84 7/21 | Stage 2 | D -36 | 2 of 9 | 0.1 | Real Estate Services | Neutral | — | — | Real Estate | 2.20 $ | +126.3 % | +167.8 % | +69.1 % | −8.1 % | — | 94 | 42 | 12.5 % | 10.6 % | 0.29 | — | 0.0 | 157.8 | 1.9 | — | — | 5.4 | — | 95.1 % | 0.0 % | -37.6 % | -22.8 % | 0.01 | — | +44.0 % | 0.0 % | 0.0 % | 0.8 | 7.3 % | 0.3 % | — |
| RCUS Arcus Biosciences Inc | 08/05 | +16 % | 40 4/22 | Stage 2 | D -34 | 0 of 9 | 3.8 | Biotechnology | Neutral | — | Healthcare | 28.20 $ | +18.3 % | +34.4 % | +233.7 % | −3.8 % | +18.2 % | 93 | 42 | 6.2 % | 6.0 % | 0.80 | — | 0.0 | 16.1 | 7.4 | — | — | 4.0 | -788.2 % | -121.6 % | -156.4 % | -70.0 % | -23.1 % | 0.22 | 52.6 % | -4.3 % | 0.0 % | 0.0 % | 1.0 | 72.4 % | 17.4 % | 1.2 (13) | |
| TSHA Taysha Gene Therapies Inc | 08/11 | +87 % | — | Stage 2 | D -31 | 4 of 9 | 0.0 | Biotechnology | Neutral | — | Healthcare | 5.60 $ | +24.7 % | +13.9 % | +178.7 % | −14.9 % | +109.3 % | 93 | 50 | 7.2 % | 6.9 % | 1.16 | — | 0.0 | — | — | — | — | -0.6 | -1,774.4 % | 100.0 % | 0.0 % | -97.3 % | -37.8 % | — | 70.6 % | +17.3 % | 0.0 % | 0.0 % | 0.4 | 95.8 % | 13.7 % | 1.0 (10) | |
| PGEN Precigen Inc | 08/11 | +125 % | 39 4/22 | Stage 2 | C +8 | 4 of 9 | 2.0 | Biotechnology | Neutral | — | — | Healthcare | 5.10 $ | +28.2 % | +41.3 % | +264.9 % | −2.8 % | +125.5 % | 93 | 42 | 6.5 % | 6.9 % | 1.01 | — | 285.7 | 62.1 | 103.2 | — | — | -3.3 | -25.8 % | -35.4 % | 0.0 % | -1,145.4 % | -42.1 % | 4.86 | 14.6 % | +146.7 % | 0.0 % | 0.0 % | -57.6 | 71.1 % | 22.4 % | 1.5 (4) |
| FTRE Fortrea Holdings Inc. | 08/05 | -17 % | 14 2/22 | Stage 2 | D -31 | 4 of 9 | 1.6 | Biotechnology | Uses AI | — | Healthcare | 17.70 $ | -4.6 % | -1.0 % | +233.7 % | −5.1 % | -7.4 % | 92 | 13 | 6.2 % | 6.3 % | 2.01 | — | 13.7 | 0.6 | — | 8.3 | 0.34 | 92.4 | 0.5 % | 18.9 % | -16.5 % | -64.6 % | -0.1 % | — | 19.6 % | +1.0 % | 0.0 % | 0.0 % | 0.8 | 110.4 % | 12.3 % | 2.0 (12) | |
| REPL Replimune Group Inc | 07/02 | -31 % | 55 5/22 | Stage 3 | D -37 | 1 of 9 | 0.9 | Biotechnology | Neutral | — | Healthcare | 10.50 $ | +17.5 % | -40.2 % | +22.1 % | −15.9 % | -4.2 % | 92 | 42 | 9.2 % | 10.0 % | 0.87 | — | 0.0 | 610.7 | 4.6 | — | — | -0.2 | — | — | 0.0 % | -90.9 % | -45.0 % | 0.36 | — | — | 0.0 % | 0.0 % | -8.4 | 96.9 % | 49.5 % | — | |
| ARMP Armata Pharmaceuticals Inc | 08/11 | +51 % | 56 5/22 | Stage 1 | D -42 | 4 of 9 | 0.2 | Biotechnology | Neutral | — | — | Healthcare | 5.10 $ | +11.6 % | +0.8 % | +299.5 % | −60.2 % | +169.2 % | 91 | 42 | 11.0 % | 10.5 % | 1.27 | — | 0.0 | 45.5 | — | — | — | -3.5 | — | -215.2 % | 0.0 % | -3,439.4 % | -25.3 % | — | — | -5.2 % | 0.0 % | 0.0 % | -52.2 | 10.5 % | 1.9 % | — |
| CLPT Clearpoint Neuro Inc | 08/11 | +61 % | 40 4/22 | Stage 3 | D -13 | 4 of 9 | 0.5 | Medical Devices | Neutral | — | — | Healthcare | 15.10 $ | +35.5 % | +34.1 % | +58.3 % | −40.3 % | +57.8 % | 90 | 42 | 11.6 % | 9.0 % | 1.24 | — | 12.1 | 13.4 | 28.7 | — | 0.61 | -7.1 | — | 62.3 % | -71.6 % | -149.7 % | -25.0 % | 3.38 | — | +17.8 % | 0.0 % | 0.0 % | -3.1 | 50.6 % | 17.0 % | — |
| SPIR Spire Global Inc | 08/12 | +124 % | 85 10/29 | Stage 2 | D -21 | 4 of 9 | 0.6 | Specialty Business Services | Sells AI | — | — | Industrials | 11.00 $ | +132.5 % | +114.7 % | +76.8 % | −38.3 % | +30.6 % | 90 | 42 | 9.1 % | 11.1 % | 2.52 | 10.3 | 0.0 | 9.3 | 7.3 | — | — | 9.9 | — | 42.3 % | 77.1 % | 101.2 % | -27.2 % | 0.13 | — | -35.2 % | 0.0 % | 0.0 % | -8.1 | 39.9 % | 12.3 % | — |
| KPTI Karyopharm Therapeutics Inc | 08/10 | -23 % | 94 9/22 | Stage 2 | D -25 | 4 of 9 | 0.2 | Biotechnology | Uses AI | — | — | Healthcare | 7.50 $ | +31.1 % | +35.0 % | +110.6 % | −13.9 % | +42.7 % | 89 | 42 | 7.7 % | 8.7 % | 0.81 | — | 0.0 | 1.4 | 12.1 | — | — | -1.9 | — | 13.5 % | -129.0 % | -891.1 % | -40.6 % | -0.87 | — | +0.6 % | 0.0 % | 0.0 % | -48.8 | 83.7 % | 24.8 % | — |
| CYTK Cytokinetics Inc | 08/06 | +8 % | 68 6/22 | Stage 2 | D -22 | 3 of 9 | 10.9 | Biotechnology | Neutral | — | Healthcare | 79.10 $ | +25.9 % | +36.0 % | +148.8 % | −2.6 % | +33.5 % | 88 | 42 | 4.6 % | 4.1 % | 0.42 | — | 117.6 | 102.5 | 60.3 | — | — | -15.8 | -948.7 % | -290.7 % | 0.0 % | -572.2 % | -31.5 % | -1.56 | -64.9 % | +376.6 % | 0.0 % | 0.0 % | -7.3 | 118.8 % | 16.8 % | 1.1 (21) | |
| ECOR Electrocore LLC | 08/05 | +35 % | 70 6/22 | Stage 2 | D -11 | 4 of 9 | 0.1 | Medical Devices | – | — | — | Healthcare | 6.10 $ | +86.2 % | +66.4 % | +47.6 % | −31.5 % | +166.6 % | 87 | 42 | 11.0 % | 11.5 % | 0.89 | — | 384.6 | 1.7 | 34.9 | — | — | 0.2 | — | 87.3 % | -44.1 % | -478.7 % | -58.1 % | -1.67 | — | +27.2 % | 0.0 % | 0.0 % | -44.7 | 9.2 % | 2.6 % | — |
| HURA TuHURA Biosciences Inc | 08/13 | -33 % | 82 7/22 | Stage 3 | E -63 | 3 of 9 | 0.2 | Biotechnology | Neutral | — | Healthcare | 2.20 $ | +248.7 % | +177.9 % | -0.4 % | −33.6 % | +210.4 % | 86 | 42 | 10.2 % | 9.0 % | — | — | 0.0 | — | — | — | — | 0.0 | — | — | 0.0 % | -187.2 % | -81.9 % | — | — | — | 0.0 % | 0.0 % | -16.0 | 15.0 % | 15.8 % | — | |
| MIRM Mirum Pharmaceuticals Inc | 08/05 | +102 % | 68 6/22 | Stage 2 | C -10 | 3 of 9 | 6.9 | Biotechnology | – | — | — | Healthcare | 116.60 $ | +40.6 % | +52.3 % | +128.7 % | −1.9 % | +24.5 % | 86 | 42 | 5.0 % | 5.0 % | 0.49 | — | 2,000.0 | 12.2 | 31.1 | — | — | 341.2 | -39.5 % | 81.4 % | -140.2 % | -335.8 % | -5.9 % | 1.34 | 27.2 % | +54.7 % | 0.0 % | 0.0 % | -5.4 | 114.4 % | 14.9 % | 1.0 (10) |
| CLMT Calumet Specialty Products Partner | 08/14 | +35 % | 99 18/23 | Stage 2 | D -13 | 3 of 9 | 3.0 | Specialty Chemicals | – | — | — | Basic Materials | 43.40 $ | +65.2 % | +81.8 % | +106.6 % | −11.6 % | +13.2 % | 86 | 95 | 4.7 % | 4.3 % | 0.72 | — | 16.3 | 0.7 | 19.3 | 35.4 | 0.65 | 106.0 | -27.8 % | 6.1 % | -4.5 % | -1,172.2 % | -2.0 % | -2.24 | -37.9 % | -1.3 % | 0.0 % | 0.0 % | 0.1 | 53.3 % | 5.9 % | 1.4 (7) |
| ATRA Atara Biotherapeutics Inc | 08/10 | -29 % | 81 7/22 | Stage 3 | D -28 | 4 of 9 | 0.1 | Biotechnology | – | — | — | Healthcare | 8.30 $ | -38.3 % | -67.1 % | +33.9 % | −46.6 % | +33.7 % | 85 | 42 | 8.3 % | 8.3 % | 0.09 | — | 232.6 | 4.0 | 16.1 | — | — | 2.2 | — | 70.1 % | -40.9 % | -2,014.9 % | -3.8 % | -0.27 | — | -6.3 % | 0.0 % | 0.0 % | -327.5 | 52.5 % | 7.8 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Going concern refers to serious doubt about whether a company can continue to operate. This scanner takes the classic warning signs: Altman Z″ in the distress zone (<1.1), interest coverage <1 (earnings don't cover interest), and negative operating cash flow (burning cash).
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 159 stocks pass this scanner's criteria (as of 21. July 2026). The 25 strongest hits are shown.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Pradeep Bonde: 4% Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.